Related Experiment Videos
Vasospasm and stroke attributable to ephedra-free xenadrine: case report
1Walter Reed Army Medical Center, Silver Spring, MD 20910, USA.
Abstract:
Following the 2004 ban of ephedra, which was linked to several cases of stroke and myocardial infarction, manufacturers have marketed "ephedra-free" weight loss products that include the active ingredient synephrine. Despite the lack of data on safety and efficacy, synephrine is touted by its promoters as a "safe" alternative to ephedra and is often combined with caffeine, as in the supplement Xenadrine-EFX. We report a case of left middle cerebral artery vasopasm and stroke in a young healthy patient in the setting of Xenadrine-EFX use.
Related Concept Videos
Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ischemic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
Ischemic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
Atherosclerosis III: Management